HWHui Wang

Hui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas Horn

    Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

    4 shared publications
  • Matthias Eiber

    TUM: Technische Universitat Munchen

    3 shared publications
  • Wolfgang Weber

    TUM: Technische Universitat Munchen

    3 shared publications
  • Christoph Würnschimmel

    Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Hans-Juergen Wester

    Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany

    2 shared publications
  • Hans-Jürgen Wester

    Pharmaceutical Radiochemistry, Technical University Munich, Munich, Germany

    2 shared publications

Latest Publications

  • Partial Remission in Pediatric Relapsed Neuroblastoma After Multiple Cycle Low-Dose 211At-MABG Therapy

    by Zitong Zhang, Hui Wang, Hongming Zhuang, Feize Li, Chunyang Nong, Yue Kang, Xia Guo, Rong Tian

    An 11-year-old boy with relapsed, poorly differentiated left adrenal neuroblastoma presented with multiple bone metastases, demonstrated by an 18 F-MFBG PET/CT with a Curie score of 4, despite prior multimodal therapy. He was subsequently enrolled in a phase 1 dose-escalation trial of 211 At-MABG-targeted alpha therapy. Follow-up 18 F-MFBG PET/CT revealed the resolution of most lesions and markedly decreased tracer uptake at the residual site, reducing his posttreatment Curie score to 1. This case highlights the therapeutic potential, safety, and feasibility of repeated, low-dose 211 At-MABG-targeted alpha therapy for pediatric relapsed neuroblastoma.

  • Increased 18F-AV1451 Retention in Soft Tissue of Patients With Progressive Supranuclear Palsy

    by Lixiang Yang, Futao Cui, Xin Li, Hui Wang

    We report 18 F-AV1451 PET/MRI findings of a 56-year-old man with progressive supranuclear palsy (PSP). The images revealed multifocal 18 F-AV1451 tracer uptake in both intracranial and extracranial regions, with increased retention in bilateral basal ganglia regions and scalp soft tissue. The findings may reflect systemic tau pathology and provide the clinical experience for the possible assessment of the disease severity.

  • 18F-FDG PET/CT Identified Rectal Malignancy Earlier Than 68Ga-FAPI PET/CT

    by Hui Wang, Minggang Su

    A 69-year-old man with esophageal cancer underwent dual-tracer PET/CT using 18F-FDG and 68Ga-FAPI during his treatment. At baseline, neither scan showed abnormal uptake in the rectum. Three months later, an interim 18F-FDG PET/CT revealed focal uptake in the rectum, while the 68Ga-FAPI PET/CT showed no abnormal findings. Seventeen months later, he received a third dual-tracer PET/CT for surveillance. Both 18F-FDG and 68Ga-FAPI PET/CT detected abnormal activity in the same area of the rectum​​​​​​. The lesion was later confirmed as adenocarcinoma by histopathology after surgery. Our case demonstrated the 18F-FDG PET/CT could identify the rectal malignancy before 68Ga-FAPI PET/CT.


  • Open Access

    Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer

    by Hui Wang, Marianne Remke, Thomas Horn, Kristina Schwamborn, Yiyao Chen, Katja Steiger, Wilko Weichert, Hans-Jürgen Wester, Margret Schottelius, Wolfgang A. Weber, et al.

    Background: Targeting prostate-specific membrane antigen (PSMA) has been highly successful for imaging and treatment of prostate cancer. However, heterogeneity in immunohistochemistry indicates limitations in the effect of imaging and radionuclide therapy of multifocal disease. 99mTc-PSMA-I&S is a γ-emitting probe, which can be used for intraoperative lesion detection and postsurgical autoradiography (ARG). We aimed to study its intraprostatic distribution and compared it with (immuno)-histopathology. Results: Seventeen patients who underwent RGS between 11/2018 and 01/2020 with a total of 4660 grids were included in the preliminary analysis. Marked intratumor and intra-patient heterogeneity of PSMA expression was detected, and PSMA negative foci were observed in all samples (100%). Heterogeneous intra-patient PSMA-ligand uptake was observed, and no significant correlation was present between the degree of heterogeneity of PSMA expression and PSMA-ligand uptake. Higher PSMA-ligand uptake was observed in GS ≥ 8 than GS < 8 (p < 0.001). The appearance of Gleason Pattern (GP) 4 was strongly associated with higher uptake (coefficient: 0.43, p < 0.001), while GP 5 also affected the uptake (coefficient: 0.07, p < 0.001). Conclusion: PSMA expression and PSMA-ligand uptake show marked heterogeneity. Prostate carcinoma with GP 4 showed significantly higher uptake compared with non-neoplastic prostate tissue. Our analyses extend the scope of applications of radiolabeled PSMA-ligands to ARG for identifying high-grade disease and using its signal as a noninvasive biomarker in prostate cancer.


  • Open Access

    Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography, histopathology and immunohistochemistry in primary prostate cancer

    by Hui Wang, Marianne Remke, Thomas Horn, Kristina Schwamborn, Yiyao Chen, Katja Steiger, Wilko Weichert, Hans-Jürgen Wester, Margret Schottelius, Wolfgang Weber, et al.

    Background Targeting prostate-specific membrane antigen (PSMA) has been highly successful for imaging and treatment of prostate cancer. However, heterogeneity in immunohistochemistry indicates limitations in the effect of imaging and radionuclide therapy of multifocal disease. 99mTc-PSMA-I&S is a γ-emitting probe, which can be used for intraoperative lesion detection and postsurgical autoradiography (ARG). We aimed to study its intraprostatic distribution and compared it with (immuno)-histopathology.Results Seventeen patients who underwent RGS between 11/2018 and 01/2020 with a total of 4660 grids were included in the preliminary analysis. Marked intratumor and intrapatient heterogeneity of PSMA expression was detected, and PSMA negative foci were observed in all samples (100%). Heterogeneous intrapatient PSMA-ligand uptake was observed, and no significant correlation was present between the degree of heterogeneity of PSMA expression and PSMA-ligand uptake. Higher PSMA-ligand uptake was observed in GS ≥ 8 than GS < 8 (p < 0.001). The appearance of GP 4 was strongly associated with higher uptake (coefficient: 0.43, p < 0.001), while GP 5 also affected the uptake (coefficient: 0.07, p < 0.001).Conclusion PSMA expression and PSMA-ligand uptake show marked heterogeneity. Prostate carcinoma with GP 4 showed significantly higher uptake compared with non-neoplastic prostate tissue. Our analyses extend the scope of applications of radiolabeled PSMA-ligands to ARG for identifying high-grade disease and using its signal as a noninvasive biomarker in prostate cancer.

  • Open Access

    PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

    by Hui Wang, Thomas Amiel, Christoph Würnschimmel, Thomas Langbein, Katja Steiger, Isabel Rauscher, Thomas Horn, Tobias Maurer, Wolfgang Weber, Hans-Juergen Wester, et al.

    Background: The prostate-specific membrane antigen (PSMA) is a relevant target in prostate cancer, and immunohistochemistry studies showed associations with outcome. PSMA-ligand positron emission tomography (PET) is increasingly used for primary prostate cancer staging, and the molecular imaging TNM classification (miTNM) standardizes its reporting. We aimed to investigate the potential of PET-imaging to serve as a noninvasive imaging biomarker to predict disease outcome in primary prostate cancer after radical prostatectomy (RP). Methods: In this retrospective analysis, 186 primary prostate cancer patients treated with RP who had undergone a 68Ga-PSMA-11 PET up to three months prior to the surgery were included. Maximum standardized uptake value (SUVmax), SUVmean, tumor volume (TV) and total lesion (TL) were collected from PET-imaging. Moreover, clinicopathological information, including age, serum prostate-specific antigen (PSA) level, and pathological characteristics, was assessed for disease outcome prediction. A stage group system for PET-imaging findings based on the miTNM framework was developed. Results: At a median follow-up after RP of 38 months (interquartile range (IQR) 22–53), biochemical recurrence (BCR) was observed in 58 patients during the follow-up period. A significant association between a positive surgical margin and miN status (miN1 vs. miN0, odds ratio (OR): 5.428, p = 0.004) was detected. miT status (miT ≥ 3a vs. miT < 3, OR: 2.696, p = 0.003) was identified as an independent predictor for Gleason score (GS) ≥ 8. Multivariate Cox regression analysis indicated that PSA level (hazard ratio (HR): 1.024, p = 0.014), advanced GS (GS ≥ 8 vs. GS < 8, HR: 3.253, p < 0.001) and miT status (miT ≥ 3a vs. miT < 3, HR: 1.941, p = 0.035) were independent predictors for BCR. For stage I disease as determined by PET-imaging, a shorter BCR-free survival was observed in the patients with higher SUVmax (IA vs. IB stage, log-rank, p = 0.022). Conclusion: Preoperative miTNM classification from 68Ga-PSMA-11 PET correlates with postoperative GS, surgical margin status and time to BCR. The association between miTNM staging and outcome proposes 68Ga-PSMA-11 PET as a novel non-invasive imaging biomarker and potentially serves for ancillary pre-treatment stratification.


  • Open Access

    PSMA-Ligand Uptake Can Serve as a Novel Biomarker in Primary Prostate Cancer to Predict Outcome After Radical Prostatectomy

    by Hui Wang, Thomas Amiel, Christoph Würnschimmel, Thomas Langbein, Katja Steiger, Isabel Rauscher, Thomas Horn, Tobias Maurer, Wolfgang Weber, Hans-Juergen Wester, et al.

    BackgroundThe prostate-specific membrane antigen (PSMA) is a relevant target in prostate cancer and immunohistochemistry studies showed associations with outcome. PSMA-ligand positron emission tomography (PET) is increasingly used for primary prostate cancer staging and the molecular imaging TNM classification (miTNM) standardizes its reporting. We aimed to investigate the potential of PET-imaging to serve as a noninvasive imaging biomarker to predict disease outcome in primary prostate cancer after radical prostatectomy (RP).MethodsIn this retrospective analysis, 186 primary prostate cancer patients treated with RP who had undergone a 68Ga-PSMA-11 PET up to three months prior to the surgery were included. Maximum standardized uptake value (SUVmax), SUVmean, tumor volume (TV) and total lesion (TL) were collected from PET-imaging. Moreover, clinicopathological information, including age, serum prostate-specific antigen (PSA) level, and pathological characteristics were assessed for disease outcome prediction. A stage group system for PET-imaging findings based on the miTNM framework was developed. ResultsAt a median follow-up after RP of 38 months (interquartile range (IQR): 22-53), biochemical recurrence (BCR) was observed in 58 patients during the follow-up period. A significant association between a positive surgical margin and miN status (miN1 vs. miN0, odds ratio (OR): 5.428, p=0.004) was detected. miT status (miT≥3a vs. miTmax (IA vs. IB stage, log-rank, p=0.022).ConclusionPreoperative miTNM classification from 68Ga-PSMA-11 PET correlates with postoperative GS, surgical margin status and time to BCR. The association between miTNM staging and outcome proposes 68Ga-PSMA-11 PET as a novel non-invasive imaging biomarker and potentially serves for ancillary pre-treatment stratification. Prospective studies with larger cohort are necessary to fully determine its use including primary prostate cancer patients with different treatments and risk categories and late-stage patients.